Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA): Clinical Trials & FDA Approval Profile

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (Global / Institutional) sponsors 44 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 26 active protocols (16 recruiting now), 8 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)2.3%
Median Closed Enrollment vs National (145 pts)43 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)44
Active Pipeline (Recruiting Now)26 (16)
Completed vs Stopped Early8 / 1 (2.3%)
Median Closed Actual Enrollment43 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Hospital Research SiteLocationShared Protocols
Amsterdam UMCAmsterdam9
UMC UtrechtUtrecht, Utrecht2
RadboudumcNijmegen, Gelderland2

Explore interactive annual charts and M&A subsidiary rollups in the Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI